OSI Pharma Sues Teva and Mylan Over Tarceva Patent

Fri, 03/20/2009 - 6:25am
NEW YORK (AP) — OSI Pharmaceuticals Inc. said Friday it is suing Teva Pharmaceutical Industries Ltd. and Mylan Inc. for patent infringement, as the companies are seeking to market a generic version of OSI's daily cancer pill Tarceva. Melville, N.Y.-based OSI said the two companies are each violating three patents on Tarceva. It said the lawsuits will prevent the Food and Drug Administration from approving either generic until May 18, 2012, unless a court overturns the patents. Tarceva, or erlotinib, is approved as a treatment for pancreatic cancer and lung cancer. OSI markets the drug with biotechnology company Genentech Inc., of San Francisco. Jerusalem-based Teva is the world's biggest generic drugmaker, and Mylan, of Pittsburgh, is also among the largest makers of generic drugs.



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.